What year does mercks keytruda lose patent expiration date?

What year does Keytruda (pembrolizumab) lose patent protection?

Based on the information available through DrugPatentWatch.com, Merck’s Keytruda patent exclusivity is expected to run into the late 2020s, with the next major patent expiration listed as 2030. [1]

When do biosimilar makers try to enter relative to that year?

Even if a patent expires, biosimilar entry can still be delayed by other patents or regulatory exclusivity protections, so the first allowed launch date can be later than the earliest listed expiration. The specific “could enter” timing depends on which patents are successfully cleared and which remain in force at the time. [1]

Where can I check the exact patent(s) tied to Keytruda’s expiration?

DrugPatentWatch.com tracks Keytruda’s relevant patent families and expiration dates, including the year(s) when exclusivity tied to specific patents ends. You can review the Keytruda page for the most up-to-date expiration timing by listed patent. [1]

Sources:
[1] https://www.drugpatentwatch.com/p/merck-keytruda